View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
  2. Company News
August 10, 2018

Deals this week: Impact Therapeutics, Sienna Biopharmaceuticals, Advanced Proteome Therapeutics

Impact Therapeutics has raised $30m through a series C financing round from Decheng Capital (Decheng).

Impact Therapeutics has raised $30m through a series C financing round from Decheng Capital (Decheng).

Free Report
img

2022: So far In Venture Capital

Global investment in 2022 has been majorly dominated by North America, Europe, and Asia Pacific, whereas the Middle East, and South and Central America have recorded low investments comparatively. In light of this, Europe and North America have been identified as the major destinations for Private Equity and Venture Capital (PE/VC) investments.   GlobalData’s whitepaper analyzes which sectors PE/VC firms have been investing in, looking at Technology, Media, and Telecom, with these sectors recording $356 billion and a deal volume of over 10,000 deals in 2022. Healthcare, Financial Services, Business & Consumer Services, and Construction sectors have also seen high investment activity by PE/VC firms, recording a deal value of over $70 billion each.   But what can this mean for you?   Understand how the Deals Database on GlobalData Explorer can be leveraged to:  
  • Track the Aggregate Investment Volumes in PE/VC-Stage firms across geographies and sectors, in addition to viewing the specific deals that drove these volumes
  • Identify the top investors already active in any sector-Geography combinations
  • Assess the Performance of Financial and Legal Advisors, supporting the Dealmaking in any segment of choice (Customizable League tables)
  • Understand what is driving the PE/VC fundraising (Deal Rationale)
  Consult our full report here and optimize your business strategy.
by GlobalData
Enter your details here to receive your free Report.

Existing investor Lilly Asian Ventures (LAV) also participated in the funding round.

Based in the US, Impact Therapeutics is a clinical-stage biopharmaceutical company engaged in the development and commercialisation of therapeutics for the treatment of cancer and other life-threatening diseases.

The company plans to use the funds towards clinical development and to advance its integrated programmes that target DNA Damage Response (DDR).

Sienna Biopharmaceuticals plans to raise $75m through a public offering of shares of its common stock.

Sienna has announced plans to raise $250m through a public offering of securities. The company intends to issue the securities periodically in any combination of common stock, preferred stock, and warrants.

Based in the US, Sienna specialises in the clinical development and commercialisation of products in aesthetics and dermatology.

The company plans to use the funds towards clinical development, working capital, and other general corporate purposes.

Latham & Watkins has been appointed as the legal adviser to the company for the offering.

“Sienna Biopharmaceuticals plans to raise $75m through a public offering of shares of its common stock.”

Advanced Proteome Therapeutics has raised C$0.4m ($0.3m) through the private placement of eight million units priced at C$0.5 ($0.38) a unit.

Each unit consists of a common share and a transferable common share purchase warrant. Each full warrant is exercisable into one common share of the company at a price of C$0.075 ($0.057) a share for 24 months.

Based in the US, Advanced Proteome Therapeutics is a developer of novel therapeutics for cancer-causing tumours.

The company plans to use the funds towards the development of drug conjugates, research and development (R&D) activities, and for working capital.

Caladrius Biosciences has raised $25m through a public offering of shares.

Based in the US, Caladrius Biosciences is a clinical-stage biopharmaceutical company that develops regenerative medicines for cardiovascular diseases.

The company plans to use the funds towards research and development (R&D) activities, working capital, business expansion, and other general corporate purposes.

Mintz Levin Cohn Ferris Glovsky and Popeo, P.C. has been appointed as the legal adviser to the company for the offering.

Karuna Pharmaceuticals has raised $42m through a series A financing round from ARCH Venture Partners, the Wellcome Trust, Steven Paul M.D., and PureTech Health.

Based in the US, Karuna Pharmaceuticals is a clinical-stage pharmaceutical company engaged in targeting muscarinic receptors for the treatment of central nervous system (CNS) disorders.

The company plans to use the funds towards the development of its drug candidates and to support expansion into other therapeutic areas.

Related Companies

Free Report
img

2022: So far In Venture Capital

Global investment in 2022 has been majorly dominated by North America, Europe, and Asia Pacific, whereas the Middle East, and South and Central America have recorded low investments comparatively. In light of this, Europe and North America have been identified as the major destinations for Private Equity and Venture Capital (PE/VC) investments.   GlobalData’s whitepaper analyzes which sectors PE/VC firms have been investing in, looking at Technology, Media, and Telecom, with these sectors recording $356 billion and a deal volume of over 10,000 deals in 2022. Healthcare, Financial Services, Business & Consumer Services, and Construction sectors have also seen high investment activity by PE/VC firms, recording a deal value of over $70 billion each.   But what can this mean for you?   Understand how the Deals Database on GlobalData Explorer can be leveraged to:  
  • Track the Aggregate Investment Volumes in PE/VC-Stage firms across geographies and sectors, in addition to viewing the specific deals that drove these volumes
  • Identify the top investors already active in any sector-Geography combinations
  • Assess the Performance of Financial and Legal Advisors, supporting the Dealmaking in any segment of choice (Customizable League tables)
  • Understand what is driving the PE/VC fundraising (Deal Rationale)
  Consult our full report here and optimize your business strategy.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena